Triathletes bring international-grade performance technology to Latin America

La Quadra, Manta, Ecuador, 18th Nov 2025 – FitHacker 5D by REVI opens its doors in Manta, marking Ecuador’s first integrated biohacking and high-tech training center. The 5-dimensional performance hub combines electro-muscular stimulation (EMS), photobiomodulation, cryotherapy, epigenetic analysis, and nutrigenomics under one roof—technologies previously available only in elite training facilities abroad.

The launch comes with a powerful endorsement from Guillermo Zambrano, Ironman World Championship competitor and founder of Endurance Precision Training (EPT), Ecuador’s leading triathlon club. Fresh from competing in Marbella alongside the world’s best, Zambrano has witnessed firsthand the technology gap separating Latin American athletes from international champions.

“Elite athletes abroad work with technology that maximizes every detail, from recovery to power,” says Zambrano. “We have the grit and the heart. When we add science to that, there is no ceiling.”

BRIDGING THE PERFORMANCE GAP

FitHacker 5D by REVI.fit addresses this gap with five integrated performance dimensions:

• TRAIN: 20-minute EMS sessions that activate deep muscle fibers unreachable in traditional gyms
• RECOVER: Photobiomodulation (red light therapy) and cryotherapy to accelerate cellular regeneration
• MEASURE: Bioimpedance analysis and epigenetic hair scanning revealing 800+ biomarkers
• FUEL: Nutrigenomic meal plans designed for individual DNA profiles
• MINDSET: Neuro-linguistic programming and binaural audio for mental optimization

“It’s like giving your body an instruction manual,” Zambrano explains. “FitHacker 5D is training with intelligence, with technology, and with an integral approach that leaves nothing to chance.”

FROM SURVIVAL TO SCIENCE

For Zambrano, who trains 100+ triathletes weekly through EPT, efficiency isn’t optional—it’s essential. “Each minute must have intention, purpose, and quality,” he says. The EMS training at FitHacker 5D delivers what would normally require an hour of traditional strength work in just 20 minutes, without the joint impact that plagues endurance athletes.

His post-competition recovery protocol has been transformed by the center’s photobiomodulation and cryotherapy technologies. “The difference between arriving destroyed the next day versus arriving ready for the next battle,” he notes. Scientific literature supports his experience: photobiomodulation increases mitochondrial ATP production by up to 200%, while cryotherapy enhances hormone regulation and reduces inflammation.

POSITIONING MANTA ON THE WORLD MAP

The partnership between EPT and FitHacker 5D by REVI.fit aims to transform Manta into an international endurance training destination. “We’re demonstrating that world-class performance has no geography—it has discipline, community, and heart,” Zambrano states.

The timing is strategic. With international triathlon events on the horizon and a growing community of performance-driven individuals, Manta is positioned to become Latin America’s answer to elite training hubs in Europe and North America.

GRAND OPENING & FREE PASS OFFER

FitHacker 5D by REVI.fit opens November 22 at La Quadra, Manta. During the pre-launch phase, prospective members can book a Free Pass to experience the complete 5D protocol. The center operates on a “tribe” model—fostering accountability and community through group experiences, not traditional gym memberships.

“This isn’t a gym,” clarifies the REVI.fit team. “This is a performance ecosystem where technology meets human potential.”

ABOUT FITHACKER 5D BY REVI.FIT

FitHacker 5D by REVI.fit is Ecuador’s first integrated biohacking and high-tech training center, combining five dimensions of performance optimization: training, recovery, measurement, nutrition, and mindset. Located in Manta, the center provides access to technologies previously available only at international elite facilities.

ABOUT GUILLERMO ZAMBRANO & EPT

Guillermo Zambrano is an Ironman World Championship competitor and founder of Endurance Precision Training (EPT), Manta’s premier triathlon club. After competing against the world’s best in Marbella, Spain, Zambrano partnered with FitHacker 5D by REVI.fit to bring international-grade performance technology to Ecuador. He trains 60+ athletes weekly, focusing on precision, efficiency, and community-driven excellence. Watch The Video Here:

CONTACT

Instagram: @reviecuador | @eptrainingteam

Media Contact

Organization: FitHacker 5D by REVI

Contact Person: REVI

Website: https://www.revi.fit

Email: Send Email

Contact Number: +593967939087

City: La Quadra

State: Manta

Country:Ecuador

Release id:37222

The post ECUADOR’S FIRST BIOHACKING CENTER LAUNCHES IN MANTA appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

C&R US Accelerates IND Success and Expands Cross-Border Partnerships.

Seoul, Korea South, 18th Nov 2025 – Established in 1997 as Korea’s first full-service Contract Research Organization (CRO), C&R Research has played a pioneering role in shaping the nation’s clinical research industry. With nearly 30 years of regulatory and operational expertise, the company has earned the trust of global pharmaceutical and biotech partners. In 2023, C&R Research expanded into the U.S. market with the launch of its subsidiary, C&R US, marking a significant step in its global growth strategy.

Jinhak Kim, President of C&R US, presenting global clinical experience at 2025 BIO USA.

Connecting the U.S. and Korea in Global Clinical Trials

Now in its second year, C&R US continues to expand its presence through trusted partnerships with U.S.-based pharmaceutical companies, biotechnology firms, and CROs.

The company has successfully supported multiple Investigational New Drug (IND) applications across key therapeutic areas, including atopic dermatitis, solid tumors, biosimilars, and medical devices, while also providing Pre-IND meeting support to help clients design efficient early-stage development strategies.

C&R Research: Gateway to Accelerated Global Market Entry

Korea ranks among the world’s leading destinations for clinical research (6th globally, with Seoul ranked 2nd among cities), supported by advanced hospital infrastructure, high-quality medical standards, and strong patient recruitment capabilities.

Based on internal benchmarking and cost comparisons, the country’s streamlined regulatory framework, featuring parallel IRB and IND review, enables faster study start-up, while overall clinical costs are estimated to be up to 40 – 50% lower than in the United States. Leveraging these advantages, C&R Research serves as a strategic bridge for biopharmaceutical partners aiming for accelerated and cost-effective global market entry.

Driving the Next Frontier: AI-Powered ‘Data CRO’

Beyond traditional CRO services, C&R Research collaborates with its subsidiary Trial Informatics (TI) to deliver AI-driven clinical data platforms, including BOIM (CTMS/EDC), ImageTrial, and CsafeR. These platforms integrate predictive analytics throughout the clinical lifecycle, reducing data processing time, optimizing protocol design, and enabling smarter, faster decision-making in global trials.

C&R Research Logo.

“By combining AI-powered systems with deep regulatory, medical, and statistical expertise, C&R Research delivers an end-to-end clinical solution that accelerates innovation and ensures quality at every stage of the development process,” the company stated.

“We are committed to serving as a trusted gateway for our clients to enter and succeed in global markets.”

For more details contact Jisung Myeong (Brand Marketing Specialist/BMS) from C&R Research Inc. at PR@cnrres.com or visit https://www.cnrres.com/en/.

Address: 

• Korea: C&R Building, 412, Yeoksam-ro, Gangnam-gu, Seoul 06199, Republic of Korea
• U.S.: 1 Broadway, 14th Floor, Cambridge, MA 02142, United States

Media Contact

Organization: C&R Research Inc.

Contact Person: Jisung Myeong (Brand Marketing Specialist/BMS)

Website: https://www.cnrres.com/en/

Email: Send Email

City: Seoul

Country:Korea South

Release id:37247

The post C&R Research Strengthens Position as Korea’s Leading Global Clinical Trial Hub appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

Denver, CO, China, 18th Nov 2025 – In the latest news, OPCO partners with GS on an institutional trading program and RWA digital finance projects. The global financial system is changing fast, and this joint holistic approach marks a major step in integrating traditional finance, digital innovation, and smarter trading—reshaping how money moves around the world.

The U.S. stock market is becoming the main anchor of this new financial landscape. Global capital is flowing back into U.S. assets for three key reasons: AI is boosting profits and corporate value; algorithm-based trading is making markets faster and more efficient; and RWA and digital-dollar ecosystems are pulling foreign money back into the U.S., reinforcing the dollar’s strength. As a result, the U.S. market is shifting from a price center into a global smart-finance hub.

After several rounds of deep discussion, OPCORPO shares a unified market view and structured plan for its multi-phase institutional trading program, designed to help investors recognize market conditions through AI-driven insights.

The program will run through several phases:
A. Enrollment: Select participating investors and institutions.
B. Strategy Setup: Define market direction and key target assets.
C. Portfolio Building: Design customized investment portfolios for each member.
D. Execution: Conduct a focused 2-month institutional trading cycle.
E. Chief Strategy Executive Officer: Benjamin Levine.

This initiative demonstrates how OPCORPO leverages AI and blockchain to advance financial innovation, building a smarter, more efficient, and more interconnected market system. It signals the arrival of a new era in global markets—driven by technology and structural transformation. The institutional program provides investors with a disciplined, intelligence-backed framework to navigate modern markets, where speed, data, and structure drive performance.

About OPCOPRO:
OPCOPRO is an institutional professional investment services provider offering institutional portfolio products across international capital markets and AI-driven high-tech industries. Its RWA-based digital finance projects are designed for the trillion-dollar U.S. market. Equity financing for the project is scheduled to begin in January 2026, with founding allocations available exclusively to members participating in the institutional trading plan. A launch and signing event will be held on the same day to unveil the technology and partnership structure.

With financing for the RWA project opening in early 2026, OPCORPO plans to expand its ecosystem, deepen technological innovation, and broaden access for global investors seeking to participate in the future of intelligent finance

Media Contact

Organization: OPCORPO

Contact Person: Jared Dalton Bohan

Website: https://www.opcopro.com/

Email: Send Email

City: Denver

State: CO

Country:China

Release id:36692

The post OPCO Announces an Institutional Trading Program and RWA-Based Digital Finance Projects appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section